7-bromo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one | 61834-97-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-bromo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one
• 英文别名: 7-Bromo-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one；7-bromo-3,5-dihydro-1H-imidazo[2,1-b]quinazolin-2-one
• CAS: 61834-97-7
• 化学式: C₁₀H₈BrN₃O
• 分子量: 266.097
• InChiKey: KPGCEBHNJLVRDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  44.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,2,3,5-tetrahydroimidazo<2,1-b>quinazolin-2(1H)-one 在 盐酸 、 溴 作用下， 以 水 、 溶剂黄146 为溶剂， 生成 7-bromo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one
  参考文献：
  名称：

  Optionally substituted

  摘要：

  1,2,3,5-四氢咪唑[2,1-b]-喹唑啉-2-酮和6-[H]-1,2,3,4-四氢嘧啶[2,1-b]-喹唑啉-2-酮或其在药学上可接受的盐是对哺乳动物，包括人类，具有抗血小板聚集、抗高血压和/或支气管扩张作用的化合物。

  公开号：

  US03932407A1

文献信息

• Optionally substituted
  申请人：Bristol-Myers Company

  公开号：US03932407A1

  公开（公告）日：1976-01-13

  Optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-ones and 6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]-quinazolin-2-ones or the pharmaceutically acceptable salts thereof are compounds useful as blood platelet anti-aggregative and/or antihypertensive and/or bronchodilator agents in mammals, including humans.

  1,2,3,5-四氢咪唑[2,1-b]-喹唑啉-2-酮和6-[H]-1,2,3,4-四氢嘧啶[2,1-b]-喹唑啉-2-酮或其在药学上可接受的盐是对哺乳动物，包括人类，具有抗血小板聚集、抗高血压和/或支气管扩张作用的化合物。
• Lachenalia jacq. f. ex Murray plant named ‘Josephine’
  申请人：AGRICULTURAL RESEARCH COUNCIL

  公开号：USPP031617P3

  公开（公告）日：2020-03-31

  A new and distinct form of Lachenalia plant characterized by a bulb plant type having a spreading growth habit of a height of 15-30 centimetres (cm) and width of 10-15 cm; a hyacinth-like yellow flower with maroon tip which displays very compact inflorescence; and further having a lanceolate leaf form.

  一种新的、独特的拉肯阿利亚植物，其特征为球茎植物类型，具有15-30厘米（cm）高、10-15厘米宽的扩展生长习性；一种水仙花般的黄色花朵，带有栗色的尖端，显示出非常紧密的花序；并且具有长剑形的叶子形态。
• Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
  申请人：Glidden Paul F.

  公开号：US20090324710A1

  公开（公告）日：2009-12-31

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，用于通过给予药剂，包括anagrelide和anagrelide衍生物，将循环血小板数量降至低于正常水平或低于正常水平，以抑制血管闭塞事件，包括栓塞。提供了包含这些药剂的方法和制药制剂。
• CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR
  申请人：Glidden Paul F.

  公开号：US20130022671A1

  公开（公告）日：2013-01-24

  Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

  提供了预防和治疗方法，以抑制血管闭塞事件，包括栓塞，通过给予药物，包括阿格列酯和阿格列酯衍生物，将循环血小板数量降低到低于正常水平或低于正常水平的水平。提供了包含这些药物的方法和制药制剂。
• Methods and compositions for treating platelet-related disorders
  申请人：Hanson R. Stephen

  公开号：US20050228001A1

  公开（公告）日：2005-10-13

  Pharmaceutical preparations comprising one or more agents that reduce the number of circulating platelets to low normal or below normal levels formulated in a delivery system are provided. The pharmaceutical preparations are useful in the prophylactic and therapeutic treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by reducing the number of circulating platelets to low normal to below normal levels.

  本发明提供的药物制剂包含一种或多种可将循环血小板数量降至正常或低于正常水平的制剂，并配制在给药系统中。这些药物制剂可用于受试者的预防性和治疗性治疗，通过将循环血小板的数量降至正常或低于正常的低水平来抑制血管闭塞事件，包括栓塞。